Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeuroMetrix Announces China Launch of Peripheral Neuropathy Diagnostic

publication date: Nov 15, 2016
NeuroMetrix, a US medical device maker, announced it will begin the China launch of DPNCheck®, a diagnostic test for peripheral neuropathy. The device was approved by the CFDA in January. A Class II Medical Device, DPNCheck measures sural nerve conduction velocity in the leg, a biomarker for peripheral neuropathy. The device will be introduced at the 20th Scientific Meeting of the Chinese Diabetes Society during November 16-19, 2016 in Xiamen, Fujian. Omron Beijing will market the device for NeuroMetrix in China. More details....

Stock Symbol: (NSDQ: NURO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital